Document Detail


Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
MedLine Citation:
PMID:  15112184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary hypertension (PH) is a rare disease with a very poor prognosis. Certain pharmacologic approaches, which reduce pulmonary arterial pressure (PAP) and thereby prevent end-stage cardiopulmonary failure, have been used during recent years. Endothelin-1 has been found to be involved in the pathogenesis of PH. The dual endothelin-receptor antagonist, bosentan, was recently approved for the treatment of pulmonary arterial hypertension. The drug is mainly cleared by hepatic elimination. Severe renal dysfunction does not affect the single-dose pharmacokinetics of bosentan to a clinically relevant extent. Whether renal replacement therapy, however, interferes with the pharmacokinetics of bosentan is unknown. The authors report on the use of bosentan (125 mg twice daily) and its pharmacokinetic monitoring in a 19-year-old woman with PH and end-stage renal disease secondary to scleroderma. Treatment was well tolerated without drug-specific adverse effects. After 12 months of treatment, pulmonary arterial pressure had normalized (48 mm Hg before start of treatment, 27 mm Hg at last follow-up). On the basis of analyzing samples from Genius-hemodialysis by a liquid chromatography assay with tandem mass spectrometry detection, the authors determined the bosentan dialysis clearance to be as low as 3.5 mL/min. Bosentan for the treatment of secondary PH seems to be safe as well as effective in end-stage renal disease patients and no adjustment of the bosentan dosing regimen appears necessary.
Authors:
Lutz Liefeldt; Paul L M van Giersbergen; Jasper Dingemanse; Birgit Rudolph; Torsten Walde; Klemens Budde; Hans-H Neumayer; Berthold Hocher
Related Documents :
21275294 - Anatomical considerations in transradial intervention.
17072494 - Open repair of pararenal aortic aneurysms: operative management, early results, and ris...
18377834 - New technique to facilitate renal revascularization with use of telescoping self-expand...
20828354 - Management of atherosclerotic renal artery stenosis.
9564904 - Pathogenesis of systemic air embolism during bronchoscopic nd:yag laser operations.
2598424 - Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  43     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-27     Completed Date:  2004-07-23     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  923-6     Citation Subset:  IM    
Affiliation:
Division of Nephrology Department of Pathology, Center for Cardiovascular Research (CCR), Charité, Humboldt-University, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / pharmacokinetics,  therapeutic use*
Female
Humans
Hypertension, Pulmonary / drug therapy*,  etiology
Kidney Failure, Chronic / complications
Scleroderma, Systemic / complications*
Sulfonamides / pharmacokinetics,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Typical MPGN with few urinary abnormalities.
Next Document:  Three diabetic peritoneal dialysis patients receiving intraperitoneal insulin with dosage adjustment...